and an estimated 1.1 million deaths a year are associated with the disease. Complications may include liver cirrhosis, liver ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Analysts estimate that Vir Biotechnology will report an earnings per share (EPS) of $-0.84. Vir Biotechnology bulls will hope ...

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

VIR-5525 has the potential to address a substantial ... of noncash stock-based compensation expense compared to $100.1 million for the same period in 2024 which included $13.6 million of stock ...

Agenus' revenues are expected to be $20.98 million, down 25.1% from the year-ago quarter. Should You Invest in Vir Biotechnology, Inc. (VIR)? Before you invest in Vir Biotechnology, Inc. (VIR ...

Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2025.

Vir Biotechnology has a consensus rating of Buy. The average one-year price target is $45.25, indicating a potential 635.77% upside. The analysis below examines the analyst ratings and average 1 ...

Richard Lepke; Senior Director, Investor Relations; Vir Biotechnology Inc. Marianne De Backer; Chief Executive Officer, Director; Vir Biotechnology Inc. Mark Eisner; ...

R&D Expenses: $118.6 million for Q1 2025, including $7 million of noncash stock-based compensation. SG&A Expenses: $23.9 ...